NCT02565576View on ClinicalTrials.gov

Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

September 29, 2015

Primary Completion Date

July 31, 2017

Study Completion Date

December 19, 2017

Conditions
Myasthenia Gravis, Generalized
Interventions
DRUG

Placebo

DRUG

CFZ533

Trial Locations (15)

2100

Novartis Investigative Site, Copenhagen

10002

Novartis Investigative Site, Taipei

13353

Novartis Investigative Site, Berlin

70403

Novartis Investigative Site, Tainan City

81377

Novartis Investigative Site, München

194354

Novartis Investigative Site, S-Petersburg

420021

Novartis Investigative Site, Kazan'

443095

Novartis Investigative Site, Samara

630087

Novartis Investigative Site, Novosibirsk

656024

Novartis Investigative Site, Barnaul

H3A 2BA

Novartis Investigative Site, Montreal

G1J 1Z4

Novartis Investigative Site, Québec

8000 C

Novartis Investigative Site, Aarhus

06120

Novartis Investigative Site, Halle/S

Unknown

Novartis Investigative Site, Taipei

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY